European Breast Cancer Therapeutics Market size is estimated to surpass USD 12.9 billion by 2028, according to a latest forecast report by Graphical Research.
The increasing prevalence and incidence rates of breast cancer is anticipated to proliferate the market growth. Breast cancer is amongst a key public health concern due to its incremental mortality and morbidity rates. Further, as per the EUROPE DONNA, in 2020, estimated incidence of breast cancer in the WHO Europe region was 576,300. The statistics suggest that the risk of breast cancer increases with age. Approximately 35% of breast cancer cases in Europe are diagnosed in women aged 50–64 and around 44% cases occur in women aged 65 & above. The rising incidence rates of breast cancer in Europe is expected to promote the market potential. Also, the rise in the geriatric population across the Europe region that is increasingly susceptible to chronic ailments such as breast cancer would drive the demand for breast cancer therapeutics.
Implementation of facilitative initiatives by public organizations and government authorities to promote the awareness regarding breast cancer is anticipated to expedite the industry growth. For instance, the EUROPA DONNA (the European Breast Cancer Coalition) is a non-profit agency that operates to promote breast cancer awareness. The organization also offers assistance to European women for improved breast cancer education, adequate screening, better treatment, and increased funding for breast cancer research. EUROPA DONNA represents the members across Europe from 47 affiliated countries. The organization has launched numerous initiatives such as Europe’s Beating Cancer Plan, Transforming Breast Cancer Initiative (TBCT), and Renewed Call for Change for ensuring optimal breast cancer care for patients in the European Union. Similarly, the European Commission Initiative on Breast Cancer (ECIBC) is another organization that works to promote the awareness and increase access to optimal breast cancer treatment. It also designs & delivers evidence-based suggestions and strategies in a Quality Assurance scheme to promote the implementation of breast cancer services in EU Member States. Such initiatives are driving the awareness regarding breast cancer, further encouraging diagnosed patients to opt for breast cancer treatment that is expected to fuel the industry demand.
Browse detailed statistical insights from the report, “Europe Breast Cancer Therapeutics Market Forecast 2028 By Therapy (Targeted Therapy, Hormonal Therapy, Chemotherapy, Immunotherapy), Research Report, Country Outlook (U.S., Canada), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share” along with the table of contents (ToC) @
The hormonal therapy segment will witness 6.7% CAGR from 2022 to 2028. Hormonal therapy limits the growth of hormone-sensitive tumors by restricting body’s ability to generate hormones. Increasing R&D investments by major companies have led to the development of novel therapeutics that have increased the efficiency and reduced the collateral tissue damage. These medications are being used in coordination with the hormonal therapy for better clinical outcomes. For instance, cyclin-dependent kinase 4 and 6 (CDK4 and CDK6) are developed to interrupt the growth and proliferation of cancerous cells. The CDK4/6 inhibitors such as abemaciclib (Verzenio), palbociclib (Ibrance), and ribociclib (Kisqali) are employed in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancers. Abemaciclib is combined with hormone therapy for the managing hormone receptor-positive, HER2-negative early breast cancers that feature high risk of recurrence.
Germany breast cancer therapeutics industry will reach USD 2.2 billion by 2028, attributed to the increasing prevalence of breast cancer, rising adoption of screening programs, etc. According to the International Agency for Research on Cancer (WHO), in 2020, breast cancer accounted for highest incidence among all types of cancer with 69,697 cases. The five-year prevalence rate of breast cancer was highest with 707.38 per 100,000 population in Germany. The high incidence and prevalence rates of breast cancer in Germany is projected to drive the demand for breast cancer therapeutics in the country. The government authorities in the country launched the breast cancer screening program for women aged between 50 & 69 and offers free mammogram every two years. Such cancer screening programs are set to promote the breast cancer detection and increase the chances of recovery & treatment.
The European breast cancer therapeutics market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2017 to 2028, for the following segments:
Europe Market, By Therapy
- Targeted Therapy
- Hormonal Therapy
The above information has been provided for the following countries: